Last quarter (Q ), Carisma Therapeutics's total revenue was $83.54M, an increase of Infinity% from the same quarter last year. In Q, Carisma Therapeutics's net income was $-20.97M. See Carisma Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	$ 94.18M	$ 94.18M	$ 40.00M	-	$ 11.24M	$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	$ 94.10M	$ 94.18M	$ 40.00M	-	-	-
Operating Expense	$ 103.65M	$ 103.65M	$ 65.91M	$ 54.70M	$ 43.49M	$ 36.87M
Operating Income	$ -88.78M	$ -88.73M	$ -25.91M	$ -54.70M	$ -32.26M	$ -36.87M
Net Non Operating Interest Income Expense	$ 1.94M	$ 1.94M	$ 1.85M	$ 17.00K	-	-
Other Income Expense	$ -15.10M	$ -14.84M	$ -24.53M	$ -51.56M	$ 11.30M	$ -70.63M
Pretax Income	$ -87.10M	$ -87.28M	$ -23.76M	$ -8.65M	$ -20.95M	$ -107.50M
Tax Provision	-	-	$ -3.88M	$ -8.27M	$ 1.45M	$ 0.00
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -86.74M	$ -86.88M	$ -19.88M	$ -380.00K	$ -22.54M	$ -107.50M
Basic EPS	-	-	-	-	-	-
Diluted EPS	-	-	-	-	-	-
Basic Average Shares	-	-	-	-	-	-
Diluted Average Shares	-	-	-	-	-	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 103.65M	$ 103.65M	$ 65.91M	$ 54.70M	$ 43.49M	$ 36.87M
Net Income From Continuing And Discontinued Operation	$ -86.88M	$ -86.88M	$ -19.88M	$ -380.00K	$ -22.40M	$ -107.50M
Normalized Income	$ -53.90M	$ -68.55M	$ -40.11M	-	$ -30.56M	$ -35.88M
Interest Expense	-	-	-	-	-	-
EBIT	$ -85.53M	$ -87.14M	$ -23.76M	$ -8.67M	$ -32.26M	$ -36.87M
EBITDA	$ -58.34M	$ -77.63M	$ -24.66M	$ -8.77M	$ -32.13M	$ -36.65M

Currency in USD

Carisma Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing